Corcept Therapeutics (CORT) Cash from Investing Activities (2012 - 2026)

Corcept Therapeutics (CORT) has 15 years of Cash from Investing Activities data on file, last reported at $4.5 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Investing Activities rose 243.24% year-over-year to $4.5 million; the trailing twelve-month figure through Mar 2026 stood at $77.5 million (up 145.1% YoY), and the FY2025 full-year result was $69.8 million, up 139.28% from the prior year.
• Cash from Investing Activities rose to $4.5 million in Q1 2026, from -$11.8 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $207.5 million in Q1 2023 to a low of -$109.6 million in Q3 2023.
• A 5-year average of -$7.5 million and a median of -$11.8 million in 2025 frame the typical range for Cash from Investing Activities.
• Peak annual rise in Cash from Investing Activities reached 510.87% in 2023, while the deepest fall reached 2187.47% in 2023.
• Tracing CORT's Cash from Investing Activities over 5 years: stood at -$17.2 million in 2022, then jumped by 199.17% to $17.1 million in 2023, then tumbled by 476.42% to -$64.4 million in 2024, then soared by 81.6% to -$11.8 million in 2025, then surged by 138.35% to $4.5 million in 2026.
• Business Quant data shows CORT's Cash from Investing Activities at $4.5 million in Q1 2026, -$11.8 million in Q4 2025, and $14.6 million in Q3 2025.